Vanguard Group Inc Nuvalent, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVL
# of Institutions
184Shares Held
54.4MCall Options Held
838KPut Options Held
116K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.52 Billion31.01% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.18MShares$317 Million11.77% of portfolio
-
Perceptive Advisors LLC New York, NY2.78MShares$211 Million4.39% of portfolio
-
Black Rock Inc. New York, NY2.71MShares$205 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$205 Million30.59% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.26B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...